Johnson & Johnson (NYSE:JNJ) Shares Down 1.9% – Time to Sell?

Johnson & Johnson (NYSE:JNJ)’s stock price dropped 1.9% during trading on Thursday . The company traded as low as $258.13 and last traded at $258.4810. 6,298,053 shares traded hands during mid-day trading, a decline of 25% from the average session volume of 8,433,620 shares. The stock had previously closed at $263.40.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer said Johnson & Johnson “will have lots of good news” from its blockbuster drug lineup, reinforcing the view that the company’s pharma portfolio could keep supporting earnings and sentiment. Jim Cramer Says Johnson & Johnson “Will Have Lots of Good News About Its Myriad Blockbuster Drugs”
• Positive Sentiment: Johnson & Johnson received FDA approval for its Dual Energy THERMOCOOL SMARTTOUCH SF Platform, a dual-energy ablation system that could strengthen its electrophysiology business and expand its medtech growth opportunity. Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform
• Positive Sentiment: Analysts and market-watch articles highlighted Johnson & Johnson as a “Strong Buy” Dividend Aristocrat and pointed to its history of earnings beats, which may be supporting confidence ahead of the next report. Will Johnson & Johnson (JNJ) Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Some commentary suggests the stock may have gotten ahead of fundamentals, with one note arguing that optimism is elevated even though Johnson & Johnson’s operating picture remains strong. Johnson & Johnson: Stronger Fundamentals, But Too Much Optimism
• Negative Sentiment: Shares had recently pulled back from their highs, suggesting some near-term pressure may be coming from profit-taking or broader rotation out of defensive names. Johnson & Johnson (JNJ) Declines More Than Market: Some Information for Investors

Wall Street Analyst Weigh In

Several analysts have commented on JNJ shares. Barclays upped their price objective on Johnson & Johnson from $234.00 to $255.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 15th. Royal Bank Of Canada restated an “outperform” rating and set a $265.00 price target on shares of Johnson & Johnson in a research note on Wednesday, April 15th. Sanford C. Bernstein increased their price target on Johnson & Johnson from $225.00 to $251.00 and gave the stock a “market perform” rating in a report on Wednesday, April 15th. Argus boosted their price objective on shares of Johnson & Johnson from $240.00 to $275.00 and gave the company a “buy” rating in a research note on Thursday, April 16th. Finally, TD Cowen started coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They set a “buy” rating and a $250.00 price objective for the company. Twenty research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $257.74.

Johnson & Johnson Price Performance

The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a fifty day simple moving average of $235.85 and a two-hundred day simple moving average of $232.52. The company has a market cap of $622.22 billion, a PE ratio of 29.88, a price-to-earnings-growth ratio of 2.62 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The business had revenue of $24.06 billion during the quarter, compared to analysts’ expectations of $23.60 billion. During the same period last year, the firm earned $2.77 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, equities analysts predict that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were issued a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s dividend payout ratio is 61.97%.

Insider Activity at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Institutional investors have recently added to or reduced their stakes in the stock. Sierra Capital LLC lifted its position in shares of Johnson & Johnson by 0.5% during the 4th quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock valued at $1,685,000 after acquiring an additional 41 shares during the period. Beaird Harris Wealth Management LLC boosted its stake in shares of Johnson & Johnson by 1.8% during the 4th quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after acquiring an additional 42 shares in the last quarter. Ballast Advisors LLC grew its holdings in shares of Johnson & Johnson by 1.2% in the 1st quarter. Ballast Advisors LLC now owns 3,598 shares of the company’s stock worth $879,000 after acquiring an additional 42 shares during the period. Broadleaf Partners LLC increased its stake in Johnson & Johnson by 0.6% in the 4th quarter. Broadleaf Partners LLC now owns 7,348 shares of the company’s stock valued at $1,521,000 after purchasing an additional 43 shares in the last quarter. Finally, Jessup Wealth Management Inc raised its holdings in Johnson & Johnson by 0.6% during the fourth quarter. Jessup Wealth Management Inc now owns 7,574 shares of the company’s stock worth $1,567,000 after purchasing an additional 44 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.